Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

NCT01309633 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: 12.5mg sunitinib with Cisplatin and Gemcitabine
DRUG: 25mg Sunitinib alternating with Cisplatin and Gemcitabine
DRUG: 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
DRUG: 2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine

Sponsor

National University Hospital, Singapore